BCL2L1 and acute myeloid leukemia: To investigate which BCL-2 protein may be the most important therapeutic target in AML we directly compared the BCL-2 inhibitor ABT-199, the BCL-xL inhibitor A1331852 and the MCL-1 inhibitor S63845 in primary blast cells isolated from AML patients (Fig. 1a).